IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes

Alessandro Del Gobbo; Annamaria Morotti; Anna Eleonora Colombo; Valentina Vaira; Giulia Ercoli; Chiara Pesenti; Eleonora Bonaparte; Elena Guerini-Rocco; Andrea Di Cristofori; Marco Locatelli; Alessandro Palleschi; Stefano Ferrero

doi:10.1007/s12032-017-1062-7

IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes

Alessandro Del Gobbo, Annamaria Morotti, Anna Eleonora Colombo, Valentina Vaira, Giulia Ercoli, Chiara Pesenti, Eleonora Bonaparte, Elena Guerini-Rocco, Andrea Di Cristofori, Marco Locatelli, Alessandro Palleschi, Stefano Ferrero

Research output: Contribution to journal › Article › peer-review

Abstract

Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3. IMP3 expression was associated with shorter overall survival in the whole series and in subgroups of metastases from non-neuroendocrine pulmonary malignancies and adenocarcinoma metastases. These results indicated that IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.

Original language	English
Pages (from-to)	2
Journal	Medical oncology (Northwood, London, England)
Volume	35
Issue number	1
DOIs	https://doi.org/10.1007/s12032-017-1062-7
Publication status	Published - Dec 1 2017

Keywords

Adenocarcinoma/mortality
Adenocarcinoma of Lung
Adult
Aged
Biomarkers, Tumor/metabolism
Brain Neoplasms/metabolism
Carcinoma, Non-Small-Cell Lung/mortality
Female
Humans
Immunohistochemistry
Lung Neoplasms/mortality
Male
Middle Aged
Neuroendocrine Tumors/metabolism
RNA-Binding Proteins/metabolism
Survival Analysis

Access to Document

10.1007/s12032-017-1062-7

Cite this

Del Gobbo, A., Morotti, A., Colombo, A. E., Vaira, V., Ercoli, G., Pesenti, C., Bonaparte, E., Guerini-Rocco, E., Di Cristofori, A., Locatelli, M., Palleschi, A., & Ferrero, S. (2017). IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes. Medical oncology (Northwood, London, England), 35(1), 2. https://doi.org/10.1007/s12032-017-1062-7

Del Gobbo, A, Morotti, A, Colombo, AE, Vaira, V, Ercoli, G, Pesenti, C, Bonaparte, E, Guerini-Rocco, E, Di Cristofori, A, Locatelli, M , Palleschi, A & Ferrero, S 2017, 'IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes', Medical oncology (Northwood, London, England), vol. 35, no. 1, pp. 2. https://doi.org/10.1007/s12032-017-1062-7

@article{ee6a0e06f660423a938449a2d33c48aa,

title = "IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes",

abstract = "Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3. IMP3 expression was associated with shorter overall survival in the whole series and in subgroups of metastases from non-neuroendocrine pulmonary malignancies and adenocarcinoma metastases. These results indicated that IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.",

keywords = "Adenocarcinoma/mortality, Adenocarcinoma of Lung, Adult, Aged, Biomarkers, Tumor/metabolism, Brain Neoplasms/metabolism, Carcinoma, Non-Small-Cell Lung/mortality, Female, Humans, Immunohistochemistry, Lung Neoplasms/mortality, Male, Middle Aged, Neuroendocrine Tumors/metabolism, RNA-Binding Proteins/metabolism, Survival Analysis",

author = "{Del Gobbo}, Alessandro and Annamaria Morotti and Colombo, {Anna Eleonora} and Valentina Vaira and Giulia Ercoli and Chiara Pesenti and Eleonora Bonaparte and Elena Guerini-Rocco and {Di Cristofori}, Andrea and Marco Locatelli and Alessandro Palleschi and Stefano Ferrero",

year = "2017",

month = dec,

day = "1",

doi = "10.1007/s12032-017-1062-7",

language = "English",

volume = "35",

pages = "2",

journal = "Medical Oncology",

issn = "1357-0560",

publisher = "Humana Press Inc.",

number = "1",

}

TY - JOUR

T1 - IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes

AU - Del Gobbo, Alessandro

AU - Morotti, Annamaria

AU - Colombo, Anna Eleonora

AU - Vaira, Valentina

AU - Ercoli, Giulia

AU - Pesenti, Chiara

AU - Bonaparte, Eleonora

AU - Guerini-Rocco, Elena

AU - Di Cristofori, Andrea

AU - Locatelli, Marco

AU - Palleschi, Alessandro

AU - Ferrero, Stefano

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3. IMP3 expression was associated with shorter overall survival in the whole series and in subgroups of metastases from non-neuroendocrine pulmonary malignancies and adenocarcinoma metastases. These results indicated that IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.

AB - Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3. IMP3 expression was associated with shorter overall survival in the whole series and in subgroups of metastases from non-neuroendocrine pulmonary malignancies and adenocarcinoma metastases. These results indicated that IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.

KW - Adenocarcinoma/mortality

KW - Adenocarcinoma of Lung

KW - Adult

KW - Aged

KW - Biomarkers, Tumor/metabolism

KW - Brain Neoplasms/metabolism

KW - Carcinoma, Non-Small-Cell Lung/mortality

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Lung Neoplasms/mortality

KW - Male

KW - Middle Aged

KW - Neuroendocrine Tumors/metabolism

KW - RNA-Binding Proteins/metabolism

KW - Survival Analysis

U2 - 10.1007/s12032-017-1062-7

DO - 10.1007/s12032-017-1062-7

M3 - Article

C2 - 29209838

SN - 1357-0560

VL - 35

SP - 2

JO - Medical Oncology

JF - Medical Oncology

IS - 1

ER -

IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes

Abstract

Keywords

Access to Document

Fingerprint

Cite this